Investment Thesis
Following a new product launch last month, Tandem Diabetes Care, Inc. (TNDM) is in the crosshairs of investors, reaching a 52-week high this week. The company is set to widen its market share as the new upgrade enhances user convenience while the main rival battles safety concerns. The management expects nearly a two-fold rise in revenue for 2019, a year the company benefited from an all-new product launch in late 2018.
After enjoying a higher base in 2019, the revenue momentum is, therefore, unlikely to persist into 2020 amid free software upgrades for